![Frontiers | The effect of organ-specific tumor microenvironments on response patterns to immunotherapy Frontiers | The effect of organ-specific tumor microenvironments on response patterns to immunotherapy](https://www.frontiersin.org/files/Articles/1030147/fimmu-13-1030147-HTML/image_m/fimmu-13-1030147-g001.jpg)
Frontiers | The effect of organ-specific tumor microenvironments on response patterns to immunotherapy
![Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications - ScienceDirect Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2473952922002890-grabsf1.jpg)
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications - ScienceDirect
![Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - ScienceDirect Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S092375342039308X-figs2.jpg)
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - ScienceDirect
![Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial | npj Breast Cancer Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial | npj Breast Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41523-021-00351-4/MediaObjects/41523_2021_351_Fig1_HTML.png)
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial | npj Breast Cancer
![Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non ... Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non ...](https://www.thelancet.com/cms/attachment/46f09260-e5fa-4083-9704-779af78fbb80/gr1.gif)
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non ...
![JCM | Free Full-Text | Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma JCM | Free Full-Text | Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma](https://www.mdpi.com/jcm/jcm-10-05339/article_deploy/html/images/jcm-10-05339-g001.png)
JCM | Free Full-Text | Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma
![Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma | Journal of Clinical Oncology Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/0/jco.ahead-of-print/jco.22.00343/20220822/images/medium/jco.22.00343t3.gif)
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma | Journal of Clinical Oncology
![Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma | Journal of Clinical Oncology Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2022/jco.2022.40.issue-13/jco.21.01601/20220419/images/large/jco.21.01601t1.jpeg)
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma | Journal of Clinical Oncology
![Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study - The Lancet Oncology Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study - The Lancet Oncology](https://www.thelancet.com/cms/asset/5d4c041e-069f-401d-94ae-665546d0108d/gr1.jpg)
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study - The Lancet Oncology
![Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results | Leukemia Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41375-021-01323-0/MediaObjects/41375_2021_1323_Fig1_HTML.png)
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results | Leukemia
![Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial - ScienceDirect Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0140673622005621-gr2.jpg)
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial - ScienceDirect
![A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL - ScienceDirect A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497120860339-grabsf1.jpg)
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL - ScienceDirect
Insertion of Nanoluc into the Extracellular Loops as a Complementary Method To Establish BRET-Based Binding Assays for GPCRs | ACS Pharmacology & Translational Science
![15015260,allen key, allen wrench,4 MM 6in T CUSHION GRIP HEX KEY,Jugenheimer Industrial Supplies, Inc. 15015260,allen key, allen wrench,4 MM 6in T CUSHION GRIP HEX KEY,Jugenheimer Industrial Supplies, Inc.](https://www.jugenheimersupplies.com/ecomm_images/items/large/cushiongrip.jpg)
15015260,allen key, allen wrench,4 MM 6in T CUSHION GRIP HEX KEY,Jugenheimer Industrial Supplies, Inc.
![Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria - European Journal of Cancer Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria - European Journal of Cancer](https://www.ejcancer.com/cms/asset/af4bbc5f-1786-45ed-9ea3-b6cf775540ab/gr3.jpg)
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria - European Journal of Cancer
![Nutrients | Free Full-Text | A Digital Therapeutic Allowing a Personalized Low-Glycemic Nutrition for the Prophylaxis of Migraine: Real World Data from Two Prospective Studies Nutrients | Free Full-Text | A Digital Therapeutic Allowing a Personalized Low-Glycemic Nutrition for the Prophylaxis of Migraine: Real World Data from Two Prospective Studies](https://pub.mdpi-res.com/nutrients/nutrients-14-02927/article_deploy/html/images/nutrients-14-02927-ag.png?1658317554)
Nutrients | Free Full-Text | A Digital Therapeutic Allowing a Personalized Low-Glycemic Nutrition for the Prophylaxis of Migraine: Real World Data from Two Prospective Studies
![Pooled analysis of nivolumab treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the United States and Germany - Singh - 2021 - Head & Neck - Wiley Online Library Pooled analysis of nivolumab treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the United States and Germany - Singh - 2021 - Head & Neck - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/b3d35ac6-4f76-4968-aaab-d467b49870dd/hed26853-fig-0002-m.jpg)
Pooled analysis of nivolumab treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the United States and Germany - Singh - 2021 - Head & Neck - Wiley Online Library
![Treatment landscape of triple-negative breast cancer — expanded options, evolving needs | Nature Reviews Clinical Oncology Treatment landscape of triple-negative breast cancer — expanded options, evolving needs | Nature Reviews Clinical Oncology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41571-021-00565-2/MediaObjects/41571_2021_565_Fig1_HTML.png)
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs | Nature Reviews Clinical Oncology
![Maternal and perinatal obesity induce bronchial obstruction and pulmonary hypertension via IL-6-FoxO1-axis in later life | Nature Communications Maternal and perinatal obesity induce bronchial obstruction and pulmonary hypertension via IL-6-FoxO1-axis in later life | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-31655-z/MediaObjects/41467_2022_31655_Fig1_HTML.png)
Maternal and perinatal obesity induce bronchial obstruction and pulmonary hypertension via IL-6-FoxO1-axis in later life | Nature Communications
![Cancers | Free Full-Text | Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis Cancers | Free Full-Text | Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis](https://www.mdpi.com/cancers/cancers-14-05051/article_deploy/html/images/cancers-14-05051-g001a.png)
Cancers | Free Full-Text | Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis
![CI-5PG JMA CISA Double Bit Key Blanks/Schlüsselrohlinge/Chiave Grezza/Clés/Llave Gorjas - - Amazon.com CI-5PG JMA CISA Double Bit Key Blanks/Schlüsselrohlinge/Chiave Grezza/Clés/Llave Gorjas - - Amazon.com](https://m.media-amazon.com/images/I/51Lnjsv78CL.jpg)
CI-5PG JMA CISA Double Bit Key Blanks/Schlüsselrohlinge/Chiave Grezza/Clés/Llave Gorjas - - Amazon.com
![Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE | Leukemia Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41375-020-0948-0/MediaObjects/41375_2020_948_Fig1_HTML.png)